Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Patients using Novo Nordisk's (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday. This information was shared at the European Congress on Obesity in Venice, Italy.
据报道，使用诺和诺德（纽约证券交易所代码：NVO）（场外交易代码：NONOF）肥胖症治疗Wegovy的患者在四年内平均体重减轻了10％。这些信息是在意大利威尼斯举行的欧洲肥胖问题大会上分享的。
What Happened: The data, derived from a large-scale study, most of which was published last year, could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug, countering the perception of it being merely a lifestyle drug, Reuters reported.
发生了什么：路透社报道，这些数据来自一项大规模研究，其中大部分于去年公布，有可能支持Novo对Wegovy的看法，因为Wegovy试图说服保险公司和政府支付该药物的成本，这与人们认为它只是一种生活方式药物的看法背道而驰。
"This is the longest study we've conducted so far of semaglutide for weight loss," stated Martin Holst Lange, Novo's head of development.
Novo开发主管马丁·霍尔斯特·兰格说：“这是迄今为止我们对索玛鲁肽进行的最长减肥研究。”
The trial involved 17,604 patients and tested Wegovy not for weight loss, but for its heart protective benefits for overweight and obese patients with preexisting heart disease but not diabetes. Participants were not required to track diet and exercise as it was not an obesity study.
该试验涉及17,604名患者，对Wegovy的测试不是减肥，而是其对已有心脏病但未患有糖尿病的超重和肥胖患者的心脏保护作用。参与者无需追踪饮食和运动情况，因为这不是一项肥胖研究。
Why It Matters: Despite supply constraints and competition from Eli Lilly, the demand for Wegovy has been on the rise. The drug's sales more than doubled to 9.38 billion kroner ($1.35 billion) in the first quarter, although this figure fell short of analysts' estimates due to pricing pressure.
为何重要：尽管存在供应限制和礼来公司的竞争，但对Wegovy的需求一直在上升。该药在第一季度的销售额翻了一番多，达到93.8亿克朗（合13.5亿美元），尽管由于定价压力，这一数字未达到分析师的预期。
Tesla CEO Elon Musk recently endorsed Novo Nordisk's Ozempic, a GLP-1 agonist primarily prescribed to manage Type 2 diabetes, and sparked a conversation about childhood obesity and potential solutions.
特斯拉首席执行官埃隆·马斯克最近认可了诺和诺德的Ozempic，这是一种 GLP-1 激动剂，主要用于治疗 2 型糖尿病，并引发了关于儿童肥胖和潜在解决方案的讨论。
On the other hand, Denmark's healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier GLP-1 drugs such as Novo Nordisk's Ozempic. This decision is expected to affect nearly half of all current GLP-1 drug users, who may switch to cheaper alternatives.
另一方面，丹麦医疗机构已决定为2型糖尿病患者提供更便宜的药物，这影响了Novo Nordisk的Ozempic等更昂贵的 GLP-1 药物的处方。预计这一决定将影响当前所有 GLP-1 吸毒者的近一半，他们可能会转向更便宜的替代品。
Price Action: On Monday, Novo Nordisk closed 3.09% higher on NYSE at $132.39, according to Benzinga Pro.
价格走势：根据Benzinga Pro的数据，周一，诺和诺德在纽约证券交易所收盘上涨3.09％，至132.39美元。
Image Via Shutterstock
图片来自 Shutterstock
译文内容由第三方软件翻译。